Simvastatin (40 mg/day), Adiponectin Levels, and Insulin Sensitivity in Subjects With the Metabolic Syndrome

Sridevi Devaraj, David Siegel, Ishwarlal Jialal

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The metabolic syndrome (MS) is characterized by low-grade inflammation and confers an increased risk for diabetes mellitus and cardiovascular disease. Statins reduce cardiovascular events in patients with the MS and have pleiotropic effects in addition to lowering low-density lipoprotein cholesterol. Because there is a paucity of data on the effect of statins on adiponectin levels and insulin sensitivity in the MS, this study was conducted to test the effect of simvastatin (40 mg/day) compared with placebo on circulating adiponectin levels and homeostasis model assessment insulin resistance in subjects with the MS in a randomized, double-blind, placebo-controlled study. Simvastatin therapy failed to affect circulating adiponectin levels or insulin sensitivity compared with placebo over 8 weeks. In conclusion, although simvastatin is anti-inflammatory, it failed to affect adiponectin levels or improve insulin sensitivity in subjects with the MS.

Original languageEnglish (US)
Pages (from-to)1397-1399
Number of pages3
JournalAmerican Journal of Cardiology
Volume100
Issue number9
DOIs
StatePublished - Nov 1 2007

Fingerprint

Simvastatin
Adiponectin
Insulin Resistance
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Placebos
LDL Cholesterol
Diabetes Mellitus
Homeostasis
Anti-Inflammatory Agents
Cardiovascular Diseases
Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Simvastatin (40 mg/day), Adiponectin Levels, and Insulin Sensitivity in Subjects With the Metabolic Syndrome. / Devaraj, Sridevi; Siegel, David; Jialal, Ishwarlal.

In: American Journal of Cardiology, Vol. 100, No. 9, 01.11.2007, p. 1397-1399.

Research output: Contribution to journalArticle

@article{550e3e6a1e344c86a188b792a0559c0e,
title = "Simvastatin (40 mg/day), Adiponectin Levels, and Insulin Sensitivity in Subjects With the Metabolic Syndrome",
abstract = "The metabolic syndrome (MS) is characterized by low-grade inflammation and confers an increased risk for diabetes mellitus and cardiovascular disease. Statins reduce cardiovascular events in patients with the MS and have pleiotropic effects in addition to lowering low-density lipoprotein cholesterol. Because there is a paucity of data on the effect of statins on adiponectin levels and insulin sensitivity in the MS, this study was conducted to test the effect of simvastatin (40 mg/day) compared with placebo on circulating adiponectin levels and homeostasis model assessment insulin resistance in subjects with the MS in a randomized, double-blind, placebo-controlled study. Simvastatin therapy failed to affect circulating adiponectin levels or insulin sensitivity compared with placebo over 8 weeks. In conclusion, although simvastatin is anti-inflammatory, it failed to affect adiponectin levels or improve insulin sensitivity in subjects with the MS.",
author = "Sridevi Devaraj and David Siegel and Ishwarlal Jialal",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.amjcard.2007.06.028",
language = "English (US)",
volume = "100",
pages = "1397--1399",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Simvastatin (40 mg/day), Adiponectin Levels, and Insulin Sensitivity in Subjects With the Metabolic Syndrome

AU - Devaraj, Sridevi

AU - Siegel, David

AU - Jialal, Ishwarlal

PY - 2007/11/1

Y1 - 2007/11/1

N2 - The metabolic syndrome (MS) is characterized by low-grade inflammation and confers an increased risk for diabetes mellitus and cardiovascular disease. Statins reduce cardiovascular events in patients with the MS and have pleiotropic effects in addition to lowering low-density lipoprotein cholesterol. Because there is a paucity of data on the effect of statins on adiponectin levels and insulin sensitivity in the MS, this study was conducted to test the effect of simvastatin (40 mg/day) compared with placebo on circulating adiponectin levels and homeostasis model assessment insulin resistance in subjects with the MS in a randomized, double-blind, placebo-controlled study. Simvastatin therapy failed to affect circulating adiponectin levels or insulin sensitivity compared with placebo over 8 weeks. In conclusion, although simvastatin is anti-inflammatory, it failed to affect adiponectin levels or improve insulin sensitivity in subjects with the MS.

AB - The metabolic syndrome (MS) is characterized by low-grade inflammation and confers an increased risk for diabetes mellitus and cardiovascular disease. Statins reduce cardiovascular events in patients with the MS and have pleiotropic effects in addition to lowering low-density lipoprotein cholesterol. Because there is a paucity of data on the effect of statins on adiponectin levels and insulin sensitivity in the MS, this study was conducted to test the effect of simvastatin (40 mg/day) compared with placebo on circulating adiponectin levels and homeostasis model assessment insulin resistance in subjects with the MS in a randomized, double-blind, placebo-controlled study. Simvastatin therapy failed to affect circulating adiponectin levels or insulin sensitivity compared with placebo over 8 weeks. In conclusion, although simvastatin is anti-inflammatory, it failed to affect adiponectin levels or improve insulin sensitivity in subjects with the MS.

UR - http://www.scopus.com/inward/record.url?scp=35348874956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348874956&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.06.028

DO - 10.1016/j.amjcard.2007.06.028

M3 - Article

VL - 100

SP - 1397

EP - 1399

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -